4/A: TransMedics Group Officer Tamer Khayal Corrects Form 4 Filing Regarding Stock Sales

Tamer Khayal, Chief Commercial Officer of TransMedics Group, files an amended Form 4 to correct a clerical error in a previous filing regarding the nature of ownership of shares sold on May 1, 2024.

Summary

• Tamer Khayal, Chief Commercial Officer of TransMedics Group, Inc. (TMDX), filed an amended Form 4 with the SEC on May 14, 2024.
• This amendment corrects a clerical error in the original Form 4 filed on May 3, 2024.
• The correction pertains to the reporting of 11,051 shares of TransMedics Group's common stock sold on May 1, 2024.
• The original filing incorrectly stated that these shares were held directly by Khayal.
• The amended form clarifies that these shares were sold by the Tamer Ibrahim Ahmed Khayal Trust.
• The filing also details multiple sales transactions of common stock by Khayal on May 1, 2024, at varying prices ranging from $105.71 to $123.66.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan established on September 6, 2023.
• Following these transactions, Khayal directly owns 20,843 shares and indirectly owns 0 shares through the Tamer Ibrahim Ahmed Khayal Trust.

Sentiment

Score: 5

Explanation: This is a neutral filing correcting a clerical error. It doesn't indicate positive or negative sentiment about the company's performance.

Industry Context

This filing is a routine disclosure related to insider trading activity and is common for publicly traded companies. It provides transparency into the transactions of company executives.

Stakeholder Impact

• The correction ensures accurate information is available to shareholders regarding insider transactions.
• The filing provides transparency to stakeholders regarding the stock transactions of a key executive.

Key Dates